Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus

References

• Steinbrook R. Facing the diabetes epidemic – mandatory reporting of glycosylated hemoglobin values in New York City. N. Engl. J. Med.354(6), 545–548 (2006).
   PubMed Web of Science ®Google Scholar
• Gan D. Diabetes Atlas. International Diabetes Federation, Brussels, Belgium (2003).
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Roglic G, Unwin N, Bennett PH et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care28(9), 2130–2135 (2005).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension37(4), 1053–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA287(19), 2570–2581 (2002).
   PubMed Web of Science ®Google Scholar
• Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectr.19(1), 25–31 (2006).
   Google Scholar
• Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), e69–e171 (2007).
   PubMed Web of Science ®Google Scholar
• Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int. J. Cardiol.105(3), 315–318 (2005).
   PubMed Web of Science ®Google Scholar
• Tomson C, Ford D, Ansell D. The UK Renal Registry: an overview. Br. J. Hosp. Med. (Lond.)69(10), 548–549 (2008).
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association SG. Standards of medical care in diabetes – 2008. Diabetes Care31(Suppl. 1), S12–S54 (2008).
   PubMed Web of Science ®Google Scholar
• UKPDS SG. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ317(7160), 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med.122(3), 290–300 (2009).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ326(7404), 1427 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr. Cardiol. Rep.6(6), 421–426 (2004).
   PubMedGoogle Scholar
• Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med.148(1), 16–29 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med.342(6), 381–389 (2000).
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract.28(2), 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• UKPDS SG. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• MMWR WR. Racial differences in trends of end-stage renal disease, by primary diagnosis--United States, 1994–2004. MMWR Morb. Mortal. Wkly Rep.56(11), 253–256 (2007).
   PubMedGoogle Scholar
• Wilcox CS. Metabolic and adverse effects of diuretics. Semin. Nephrol.19(6), 557–568 (1999).
   PubMed Web of Science ®Google Scholar
• Greenberg A. Diuretic complications. Am. J. Med. Sci.319(1), 10–24 (2000).
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension48(2), 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Carter BL, Einhorn PT, Brands M et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension52(1), 30–36 (2008).
   PubMed Web of Science ®Google Scholar
• Opie L. Angiotensin-Converting Enzyme Inhibitors: the Advance Continues. 3rd Edition. University of Cape Town Press, South Africa, 64–67; 222–224 (1999).
   Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med.321(13), 868–873 (1989).
   PubMed Web of Science ®Google Scholar
• Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism44(1), 85–89 (1995).
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes. Metab.5(4), 214–222 (2003).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol.91(12A), 30H–37H (2003).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Renin–angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab.30(6), 498–505 (2004).
   PubMed Web of Science ®Google Scholar
• Blendea MC, Jacobs D, Stump CS et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am. J. Physiol. Endocrinol. Metab.288(2), E353–E359 (2005).
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation109(17), 2054–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care28(9), 2261–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369(9557), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension5(5 Pt 2), III132–III138 (1983).
   PubMedGoogle Scholar
• Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J. Cardiovasc. Pharmacol.7(Suppl. 1), S52–S55 (1985).
   PubMed Web of Science ®Google Scholar
• Parati G, omboni S, Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide and their different combinations assessed by 24h ambulatory blood pressure monitoring. J. Hypertens.2(Suppl.), S309 (2005).
   Google Scholar
• Eriksson JW, Jansson PA, Carlberg B et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) study. Hypertension52(6), 1030–1037 (2008).
   PubMed Web of Science ®Google Scholar
• Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am. J. Hypertens.8(3), 276–281 (1995).
   PubMed Web of Science ®Google Scholar
• Hunter SJ, Wiggam MI, Ennis CN et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet. Med.16(6), 482–487 (1999).
   PubMedGoogle Scholar
• McLaughlin DM, Atkinson AB, Ennis CN et al. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabet. Med.25(5), 631–634 (2008).
   PubMedGoogle Scholar
• Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet370(9590), 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care29(12), 2592–2597 (2006).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern. Med.47(5), 361–366 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J. Effect of two antihypertensive combinations on metabolic control in Type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J. Hum. Hypertens.15(12), 849–856 (2001).
   PubMed Web of Science ®Google Scholar
• Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am. J. Hypertens.16(5 Pt 1), 381–386 (2003).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with Type 2 diabetes mellitus. Hypertens. Res.31(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am. J. Physiol.255(6 Pt 1), E769–E774 (1988).
   PubMed Web of Science ®Google Scholar
• Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest.82(6), 1848–1852 (1988).
   PubMed Web of Science ®Google Scholar
• Bell DS. β-adrenergic blocking agents in patients with diabetes – friend and foe. Endocr. Pract.5(1), 51–53 (1999).
   PubMedGoogle Scholar
• Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med.126(12), 955–959 (1997).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292(18), 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas M, Reicher-Reiss H, Boyko V et al. Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am. J. Cardiol.77(15), 1273–1277 (1996).
   PubMedGoogle Scholar
• Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with Type 2 diabetes: the SMOOTH study. Cardiovasc. Diabetol.6, 28 (2007).
   PubMed Web of Science ®Google Scholar
• Elliot WJ. Cyclic and circadian variations in cardiovascular events. Am. J. Hypertens.14(9 Pt 2), 291S–295S (2001).
   PubMedGoogle Scholar
• Sowers JR, Neutel JM, Saunders E et al. Antihypertensive efficacy ofiIrbesartan/HCTZ in men and women with the metabolic syndrome and Type 2 diabetes. J. Clin. Hypertens. (Greenwich)8(7), 470–480 (2006).
   PubMedGoogle Scholar
• Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and Type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin. Ther.30(12), 2354–2365 (2008).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet351(9118), 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Castro J, Kaur J et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J. Clin. Hypertens. (Greenwich)7(2), 73–80 (2005).
   PubMedGoogle Scholar
• Sowers JR, Lastra G, Rocha R, Seifu Y, Crikelair N, Levy DG. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J. Clin. Hypertens. (Greenwich)10(9), 668–676 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrier C, Ferrari P, Weidmann P, Keller U, Beretta-Piccoli C, Riesen WF. Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care14(10), 911–914 (1991).
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Lazzari P et al. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur. J. Clin. Pharmacol.59(4), 271–275 (2003).
   PubMed Web of Science ®Google Scholar
• Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens.18(10), 687–691 (2004).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Achieving goal blood pressure in patients with Type 2 diabetes: conventional versus fixed-dose combination approaches. J. Clin. Hypertens. (Greenwich)5(3), 202–209 (2003).
   PubMedGoogle Scholar
• Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens.24(1), 185–192 (2006).
   PubMed Web of Science ®Google Scholar
• Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J. Clin. Hypertens. (Greenwich)9(2), 120–127 (2007).
   PubMedGoogle Scholar
• Roca-Cusachs A, Schmieder RE, Triposkiadis F et al. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J. Hypertens.26(4), 813–818 (2008).
   PubMed Web of Science ®Google Scholar
• Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with Type 2 diabetes (ATTEST) study. Hypertens. Res.31(8), 1499–1508 (2008).
   PubMedGoogle Scholar
• Kloner RA, Neutel J, Roth EM et al. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. Ann. Pharmacother.42(11), 1552–1562 (2008).
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin-Angiotensin-Aldosterone System8(4), 190–200 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor A, Tschope D, Kilo C, Ibram G, Fang H, Satlin A. Adding aliskiren to ramipril improves 24-hour blood pressure control compared to ramipril alone in patients with diabetes and hypertension. J. Hypertens.24(Suppl. 4), S81. Abstract P84.268 (2006).
   Google Scholar
• Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an α-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in Type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron80(2), 175–182 (1998).
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Viberti G, Halimi S et al. Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER. Hypertension41(5), 1063–1071 (2003).
   PubMed Web of Science ®Google Scholar
• PROGRESS SG. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart J.24(5), 475–484 (2003).
   PubMed Web of Science ®Google Scholar
• Berthet K, Neal BC, Chalmers JP et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Pressure13(1), 7–13 (2004).
   PubMed Web of Science ®Google Scholar
• Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care21(4), 597–603 (1998).
   PubMed Web of Science ®Google Scholar
• Nosadini R, Tonolo G. Cardiovascular and renal protection in Type 2 diabetes mellitus: the role of calcium channel blockers. J. Am. Soc. Nephrol.13(Suppl. 3), S216–S223 (2002).
   PubMedGoogle Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med.340(9), 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Gaxiola E, Messerli FH et al. Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension44(5), 637–642 (2004).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351(19), 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens.26(11), 2103–2111 (2008).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Does it matter how hypertension is controlled? N. Engl. J. Med.359(23), 2485–2488 (2008).
   PubMed Web of Science ®Google Scholar
• Aguilar D, Solomon SD, Kober L et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation110(12), 1572–1578 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• de Pablos-Velasco PL, Pazos Toral F, Esmatjes JE et al. Losartan titration versus diuretic combination in Type 2 diabetic patients. J. Hypertens.20(4), 715–719 (2002).
   PubMed Web of Science ®Google Scholar
• Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ305(6860), 981–985 (1992).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int.54(4), 1283–1289 (1998).
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive Type 2 diabetic patients. Am. J. Hypertens.15(12), 1042–1049 (2002).
   PubMed Web of Science ®Google Scholar
• Winer N, Folker A, Murphy JA et al. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with Type 2 diabetes. Prev. Cardiol.8(2), 87–92 (2005).
   PubMedGoogle Scholar
• Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. J. Am. Soc. Nephrol.16(Suppl. 1), S42–S47 (2005).
   PubMedGoogle Scholar
• Nakamura T, Inoue T, Fujiwara N et al. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin. Nephrol.70(5), 385–392 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev. Cardiovasc. Ther.6(10), 1347–1355 (2008).
   PubMedGoogle Scholar
• Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res.19(1), 31–36 (1996).
   PubMedGoogle Scholar
• Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles – with special references to glomerular hypertension. Am. J. Nephrol.23(4), 229–244 (2003).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res.100(3), 342–353 (2007).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int.73(11), 1303–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Fogari R, Corradi L, Zoppi A et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with Type II diabetes and microalbuminuria. Am. J. Hypertens.20(10), 1092–1096 (2007).
   PubMedGoogle Scholar
• Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am. J. Hypertens.20(4), 417–422 (2007).
   PubMed Web of Science ®Google Scholar
• Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372(9638), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med.148(1), 30–48 (2008).
   PubMed Web of Science ®Google Scholar
• Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med.24(5), 486–493 (2007).
   PubMed Web of Science ®Google Scholar
• Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol.38(4), 157–161 (2001).
   PubMedGoogle Scholar
• Andersen NH, Poulsen PL, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care28(2), 273–277 (2005).
   PubMed Web of Science ®Google Scholar
• Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J. Investig. Med.56(4), 714–719 (2008).
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med.358(23), 2433–2446 (2008).
   PubMed Web of Science ®Google Scholar
• Ingelfinger JR. Aliskiren and dual therapy in Type 2 diabetes mellitus. N. Engl. J. Med.358(23), 2503–2505 (2008).
   PubMed Web of Science ®Google Scholar
• Pedersen MM, Hansen KW, Schmitz A, Sorensen K, Christensen CK, Mogensen CE. Effects of ACE inhibition supplementary to β blockers and diuretics in early diabetic nephropathy. Kidney Int.41(4), 883–890 (1992).
   PubMedGoogle Scholar
• Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. β-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J. Diabetes Complications22(5), 303–308 (2008).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Treatment of hypertension in patients with diabetes. Arch. Intern. Med.164(17), 1850–1857 (2004).
   PubMedGoogle Scholar
• Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care25(1), 134–147 (2002).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12), 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension49(1), 69–75 (2007).
   PubMed Web of Science ®Google Scholar
• Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int.31(5), 1153–1159 (1987).
   PubMed Web of Science ®Google Scholar
• Halimi JM, Mimran A. ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? Curr. Hypertens. Rep.11(2), 85–87 (2009).
   PubMedGoogle Scholar
• Berns JS. Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am. J. Kidney Dis.53(2), 192–196 (2009).
   PubMed Web of Science ®Google Scholar
• Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with Type 2 diabetes: update after recent clinical trials. Vasc. Health Risk Manag.5(1), 411–427 (2009).
   PubMedGoogle Scholar